• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail
-

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Show All Studies
Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
General
Application Number P130004
Current Protocol Accepted 07/21/2016
Study Name OSB Lead-Device Exposure Registry Study
Study Status Study Pending
General Study Protocol Parameters
Study Design Retrospective Cohort Study
Study involve follow-up of premarket cohort (Y/N) No
Data Source Sponsor Registry
Comparison Group No Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description The objective of this study is to collect post-approval data relative to the

incidence of endophthalmitis   show the rest ...
Study Population Description The study population is defined as all patients who receive at least one application of   show the rest ...
Sample Size A sample of 4857 patients provides approximately 82% power (alpha = 0.05) to detect a   show the rest ...
Data Collection The primary endpoint will be the occurrence of endophthalmitis (based on

the ‘specific’ definition) within 30   show the rest ...
Followup Visits and Length of Followup As a retrospective study, there is technically no follow-up. The study is designed primarily to   show the rest ...


OSB Lead-Device Exposure Registry Study Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Reporting Status
six month report 07/09/2014 07/28/2014 Overdue/Received
one year report 01/08/2015 02/26/2015 Overdue/Received
18 month report 07/09/2015 07/08/2015 On Time
three year report 01/07/2017    
four year report 01/07/2018    
five year report 01/07/2019    

Show All Studies

-
-